Bachem Holding AG

BATS-CHIXE:BANBZ Stock Report

Market Cap: CHF 4.2b

Bachem Holding Valuation

Is BANBZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BANBZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 26.02
Fair Value
116.0% overvalued intrinsic discount
7
Number of Analysts

Below Fair Value: BANBZ (CHF56.2) is trading above our estimate of fair value (CHF26.02)

Significantly Below Fair Value: BANBZ is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BANBZ?

Key metric: As BANBZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BANBZ. This is calculated by dividing BANBZ's market cap by their current earnings.
What is BANBZ's PE Ratio?
PE Ratio37x
EarningsCHF 113.57m
Market CapCHF 4.21b

Price to Earnings Ratio vs Peers

How does BANBZ's PE Ratio compare to its peers?

The above table shows the PE ratio for BANBZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average52.3x
HVO hVIVO
7.1x-29.6%UK£123.1m
HIK Hikma Pharmaceuticals
19.8x11.0%UK£4.6b
GNS Genus
149.8x36.9%UK£1.2b
SFZN Siegfried Holding
32.7x13.0%CHF 4.2b
BANBZ Bachem Holding
37x17.8%CHF 4.2b

Price-To-Earnings vs Peers: BANBZ is good value based on its Price-To-Earnings Ratio (37x) compared to the peer average (52.3x).

Price to Earnings Ratio vs Industry

How does BANBZ's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BANBZ is expensive based on its Price-To-Earnings Ratio (37x) compared to the European Life Sciences industry average (36.3x).

Price to Earnings Ratio vs Fair Ratio

What is BANBZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BANBZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37x
Fair PE Ratio29.2x

Price-To-Earnings vs Fair Ratio: BANBZ is expensive based on its Price-To-Earnings Ratio (37x) compared to the estimated Fair Price-To-Earnings Ratio (29.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BANBZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 56.20
CHF 76.86
+36.8%
16.3%CHF 100.00CHF 58.00n/a7
Jan ’26CHF 58.00
CHF 83.57
+44.1%
13.8%CHF 100.00CHF 71.00n/a7
Dec ’25CHF 67.90
CHF 84.43
+24.3%
12.7%CHF 100.00CHF 71.00n/a7
Nov ’25CHF 70.05
CHF 84.83
+21.1%
13.2%CHF 100.00CHF 71.00n/a6
Oct ’25CHF 70.00
CHF 82.83
+18.3%
16.0%CHF 100.00CHF 65.00n/a6
Sep ’25CHF 81.55
CHF 82.83
+1.6%
16.0%CHF 100.00CHF 65.00n/a6
Aug ’25CHF 79.28
CHF 77.14
-2.7%
22.9%CHF 100.00CHF 52.00n/a7
Jul ’25CHF 83.48
CHF 75.67
-9.4%
22.1%CHF 100.00CHF 52.00n/a6
Jun ’25CHF 80.05
CHF 70.80
-11.6%
19.6%CHF 85.00CHF 52.00n/a5
May ’25CHF 80.50
CHF 70.80
-12.0%
19.6%CHF 85.00CHF 52.00n/a5
Apr ’25CHF 86.10
CHF 70.80
-17.8%
19.6%CHF 85.00CHF 52.00n/a5
Mar ’25CHF 70.15
CHF 71.17
+1.4%
17.6%CHF 85.00CHF 52.00n/a6
Feb ’25CHF 58.03
CHF 71.17
+22.6%
17.6%CHF 85.00CHF 52.00n/a6
Jan ’25CHF 65.00
CHF 73.17
+12.6%
13.7%CHF 85.00CHF 56.00CHF 58.006
Dec ’24CHF 64.95
CHF 75.33
+16.0%
9.3%CHF 85.00CHF 64.00CHF 67.906
Nov ’24CHF 66.05
CHF 75.33
+14.1%
9.3%CHF 85.00CHF 64.00CHF 70.056
Oct ’24CHF 67.65
CHF 77.00
+13.8%
12.7%CHF 95.00CHF 64.00CHF 70.006
Sep ’24CHF 82.20
CHF 80.00
-2.7%
14.1%CHF 97.00CHF 65.00CHF 81.557
Aug ’24CHF 80.10
CHF 82.83
+3.4%
13.6%CHF 97.00CHF 65.00CHF 79.286
Jul ’24CHF 77.75
CHF 87.60
+12.7%
9.3%CHF 97.00CHF 74.00CHF 83.485
Jun ’24CHF 93.55
CHF 91.75
-1.9%
4.8%CHF 97.00CHF 86.00CHF 80.054
May ’24CHF 96.90
CHF 88.20
-9.0%
11.2%CHF 100.00CHF 71.00CHF 80.505
Apr ’24CHF 91.95
CHF 88.20
-4.1%
11.2%CHF 100.00CHF 71.00CHF 86.105
Mar ’24CHF 94.00
CHF 88.20
-6.2%
11.2%CHF 100.00CHF 71.00CHF 70.155
Feb ’24CHF 80.70
CHF 86.80
+7.6%
11.7%CHF 100.00CHF 71.00CHF 58.035
Jan ’24CHF 80.45
CHF 86.80
+7.9%
11.7%CHF 100.00CHF 71.00CHF 65.005
Analyst Price Target
Consensus Narrative from 7 Analysts
CHF 76.99
Fair Value
27.0% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 13:04
End of Day Share Price 2025/01/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bachem Holding AG is covered by 23 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Konstantin WiechertBaader Helvea Equity Research